Bessemer Group
PTGX icon

Bessemer Group’s Protagonist Therapeutics PTGX Stock Holding History

Bessemer Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.38M Sell
52,074
-2,104
-4% -$220K 0.01% 513
2026
Q1 		$5.71M Buy
54,178
+16
+0% +$1.42K 0.01% 444
2025
Q4 		$4.73M Buy
54,162
+49,887
+1,167% +$4.08M 0.01% 428
2025
Q3 		$283K Buy
4,275
+3,771
+748% +$214K ﹤0.01% 1036
2025
Q2 		$28K Buy
504
+318
+171% +$15.3K ﹤0.01% 1473
2025
Q1 		$9K Sell
186
-15
-7% -$629 ﹤0.01% 1825
2024
Q4 		$8K Buy
201
+107
+114% +$4.67K ﹤0.01% 1870
2024
Q3 		$4K Buy
+94
New +$3.8K ﹤0.01% 2031
2020
Q3 		– Sell
-53,500
Closed -$945K – 1603
2020
Q2 		$945K Buy
+53,500
New +$671K ﹤0.01% 813

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bessemer Group's PTGX Position: Q2 2026 in Review

Bessemer Group reduced its Protagonist Therapeutics (PTGX) stake by 3.9% in Q2 2026, selling an estimated $220K and leaving 52,074 shares worth $6.38M. The position accounts for 0.01% of the portfolio, ranked #513.

Bessemer Group first reported a position in PTGX in Q2 2020 and has held it in 9 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Bessemer Group held 52,074 shares of Protagonist Therapeutics worth $6.38M as of Q2 2026.
  • Bessemer Group sold 2,104 Protagonist Therapeutics shares in Q2 2026, an estimated $220K.
  • Protagonist Therapeutics made up 0.01% of Bessemer Group's portfolio in Q2 2026, its #513 holding.
  • Bessemer Group first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 9 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.